Assuming the data in this Phase III hold up to what was seen for the subset of patients from the Phase II that the company is now targeting - 2023 could be a big year. The end of 2022 could be kind of fun as well.
As the interim analysis is coming (July 2022) I start to dig ... more is necessary but the first thought (after a short / 1 hour DD): I guess they will raise cash based on the interim announcement.
I will make a more deeper, prudent DD ... but looks like I will jump in before the end of June ... before 26 June.
News 
Market Data 
Discover 
AI
